168 related articles for article (PubMed ID: 36097108)
1. Effects of thiostrepton alone or in combination with selumetinib on triple-negative breast cancer metastasis.
Demirtas Korkmaz F; Dogan Turacli I; Esendagli G; Ekmekci A
Mol Biol Rep; 2022 Nov; 49(11):10387-10397. PubMed ID: 36097108
[TBL] [Abstract][Full Text] [Related]
2. Identification of FOXM1 as a specific marker for triple‑negative breast cancer.
Tan Y; Wang Q; Xie Y; Qiao X; Zhang S; Wang Y; Yang Y; Zhang B
Int J Oncol; 2019 Jan; 54(1):87-97. PubMed ID: 30365046
[TBL] [Abstract][Full Text] [Related]
3. Thiostrepton confers protection against reactive oxygen species-related apoptosis by restraining FOXM1-triggerred development of gastric cancer.
Liu SX; Zhou Y; Zhao L; Zhou LS; Sun J; Liu GJ; Du YS; Zhou YN
Free Radic Biol Med; 2022 Nov; 193(Pt 1):385-404. PubMed ID: 36152915
[TBL] [Abstract][Full Text] [Related]
4. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
[TBL] [Abstract][Full Text] [Related]
5. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
[TBL] [Abstract][Full Text] [Related]
6. c-FLIP promotes drug resistance in non-small-cell lung cancer cells via upregulating FoxM1 expression.
Wang WD; Shang Y; Wang C; Ni J; Wang AM; Li GJ; Su L; Chen SZ
Acta Pharmacol Sin; 2022 Nov; 43(11):2956-2966. PubMed ID: 35422085
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J
Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278
[TBL] [Abstract][Full Text] [Related]
8. Expression of Forkhead box M1 in soft tissue leiomyosarcoma: Clinicopathologic and in vitro study using a newly established cell line.
Maekawa A; Kohashi K; Setsu N; Kuda M; Iura K; Ishii T; Matsunobu T; Nakatsura T; Iwamoto Y; Oda Y
Cancer Sci; 2016 Jan; 107(1):95-102. PubMed ID: 26560505
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
10. Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial‑to-mesenchymal transition pathway.
Yu C; Chen L; Yie L; Wei L; Wen T; Liu Y; Chen H
Oncol Rep; 2015 May; 33(5):2402-10. PubMed ID: 25738652
[TBL] [Abstract][Full Text] [Related]
11. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.
Bartholomeusz C; Xie X; Pitner MK; Kondo K; Dadbin A; Lee J; Saso H; Smith PD; Dalby KN; Ueno NT
Mol Cancer Ther; 2015 Dec; 14(12):2773-81. PubMed ID: 26384399
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma.
Jiang L; Wang P; Chen H
Ups J Med Sci; 2014 Nov; 119(4):324-32. PubMed ID: 25231007
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
[TBL] [Abstract][Full Text] [Related]
14. Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs.
Guillen VS; Ziegler Y; Gopinath C; Kumar S; Dey P; Plotner BN; Dawson NZ; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
Breast Cancer Res Treat; 2023 Apr; 198(3):607-621. PubMed ID: 36847915
[TBL] [Abstract][Full Text] [Related]
15. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
[TBL] [Abstract][Full Text] [Related]
17. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.
Lok GT; Chan DW; Liu VW; Hui WW; Leung TH; Yao KM; Ngan HY
PLoS One; 2011; 6(8):e23790. PubMed ID: 21858223
[TBL] [Abstract][Full Text] [Related]
18. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
[TBL] [Abstract][Full Text] [Related]
19. FOXM1: a new therapeutic target of extramammary Paget disease.
Ito T; Tanaka Y; Kaku-Ito Y; Oda Y; Nakahara T
Sci Rep; 2024 Feb; 14(1):4048. PubMed ID: 38374400
[TBL] [Abstract][Full Text] [Related]
20. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer.
Katzenellenbogen BS; Guillen VS; Katzenellenbogen JA
Breast Cancer Res; 2023 Jun; 25(1):76. PubMed ID: 37370117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
